BioNxt Solutions (BNXTF) Stock Price, News & Analysis

Company Overview

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $0.28 to $0.30
• 50-Day Range: $0.18 to $0.32
• 52-Week Range: $0.11 to $0.51
• Volume: 3,400 shs
• Average Volume: 1,040 shs
• Market Capitalization: $33.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BNXTF Stock Analysis - Frequently Asked Questions

How have BNXTF shares performed this year?

BioNxt Solutions' stock was trading at $0.2519 at the beginning of 2025. Since then, BNXTF stock has increased by 18.7% and is now trading at $0.2989.
View the best growth stocks for 2025 here.

How were BioNxt Solutions' earnings last quarter?

BioNxt Solutions Inc. (OTCMKTS:BNXTF) announced its quarterly earnings results on Friday, November, 29th. The company reported ($0.01) earnings per share for the quarter.

How do I buy shares of BioNxt Solutions?

Shares of BNXTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/29/2024
• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BNXTF
• CUSIP: N/A
• CIK: N/A
• Web: www.xphyto.com
• Phone: 780-818-6422
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,720,000.00
• Net Margins: -15,638.71%
• Pretax Margin: -15,380.65%
• Return on Equity: N/A
• Return on Assets: -683.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: $280,000.00
• Price / Sales: 121.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -7.47

Miscellaneous

• Outstanding Shares: 113,400,000
• Free Float: N/A
• Market Cap: $33.90 million
• Optionable: Not Optionable
• Beta: 0.67